Misplaced Pages

This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 19:47, 13 January 2011 (moved SCH-530,348 to Vorapaxar: current generic drug name). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (February 2009)

Vorapaxar

Identifiers
IUPAC name Ethyl N-vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzoisobenzofuran-7-yl]carbamate
CAS Number	618385-01-6
PubChem CID	10077130
CompTox Dashboard (EPA)	DTXSID201009336
ECHA InfoCard	100.116.767
Chemical and physical data
Formula	C29H33FN2O4
Molar mass	492.58 g/mol g·mol

SCH-530,348 is a thrombin receptor (PAR-1) antagonist based on the natural product himbacine. Developed by Schering-Plough, SCH-530,348 is a potential treatment for acute coronary syndrome chest pain caused by coronary artery disease.

Now owned by Merck, this compound is being called Vorapaxar.

References

1. Samuel Chackalamannil (2008). "Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity". Journal of Medicinal Chemistry. 51: 3061. doi:10.1021/jm800180e.

External links

• C&EN
• ChemSpider Article

• Orphaned articles from February 2009
• Carbamates
• Pyridines
• Organofluorides
• Benzoisobenzfurans